| 000 | 01718 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250513221856.0 | ||
| 264 | 0 | _c20001017 | |
| 008 | 200010s 0 0 eng d | ||
| 022 | _a0008-543X | ||
| 024 | 7 |
_a10.1002/1097-0142(20001001)89:7<1547::aid-cncr19>3.0.co;2-p _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPapadimitriou, C A | |
| 245 | 0 | 0 |
_aPaclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: long-term results of a phase II study. _h[electronic resource] |
| 260 |
_bCancer _cOct 2000 |
||
| 300 |
_a1547-54 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aCisplatin _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aEpirubicin _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGranulocyte Colony-Stimulating Factor _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aPaclitaxel _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aMoulopoulos, L A | |
| 700 | 1 | _aVlahos, G | |
| 700 | 1 | _aVoulgaris, Z | |
| 700 | 1 | _aKiosses, E | |
| 700 | 1 | _aGeorgoulias, N | |
| 700 | 1 | _aGika, D | |
| 700 | 1 | _aDiakomanolis, E | |
| 700 | 1 | _aMichalas, S | |
| 700 | 1 | _aDimopoulos, M A | |
| 773 | 0 |
_tCancer _gvol. 89 _gno. 7 _gp. 1547-54 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/1097-0142(20001001)89:7<1547::aid-cncr19>3.0.co;2-p _zAvailable from publisher's website |
| 999 |
_c10959170 _d10959170 |
||